{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03061812: Phase 3 Interventional Completed Small Cell Lung Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02289846: Phase 2 Interventional Completed Diabetic Gastroparesis
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01135108: Phase 2 Interventional Completed Spinal Cord Injury
(2009)
Source URL:
Class:
PROTEIN
KAI 1678 is a first-in-class, isoenzyme selective, a small peptide inhibitor of protein kinase C epsilon. It was in development for the treatment of neuropathic and postoperative pain. However, KAI-1678 treatment results were negative.
Class:
PROTEIN
Status:
Investigational
Source:
NCT02237950: Phase 3 Interventional Completed Bacterial Vaginosis
(2014)
Source URL:
Class:
PROTEIN
Conditions:
Astodrimer, also known as SPL7013, a microbicide developed by Starpharm. This drug has been used in phase III clinical trials for the treatment and prevention of Bacterial Vaginosis. Starpharma conducts a meeting with US FDA related to potential approval of astodrimer in Bacterial vaginosis. In addition, SPL7013, participated in phase II clinical trials against human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2). It is known that astodrimer binds tightly to R5 gp120 in the gp120-CD4 complex, thus preventing the accrual of the requisite number of gp120-CD4 complexes across the virus-cell interface, thereby blocking virus entry.
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02449239: Phase 3 Interventional Completed Bladder Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02371668: Phase 2 Interventional Completed H1N1 Influenza Healthy Volunteers
(2015)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
